Quick Overview.
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for the treatment of type 2 diabetes and later approved for chronic weight management. It works by mimicking the incretin hormone GLP-1, which increases insulin secretion, decreases glucagon secretion, and delays gastric emptying, leading to reduced appetite and caloric intake. It is widely considered one of the most effective pharmacological interventions for weight loss currently available.
Primary Use Case: Significant weight loss and glycemic control. Who it is for: Individuals with obesity or overweight with weight-related comorbidities, and patients with type 2 diabetes.
Turn this protocol into your actual schedule.
Log every dose, every side-effect, and every PR on one timeline.
The Protocol & Usage Guide.
Before you start: Ensure you have a clear understanding of the titration schedule to minimize gastrointestinal side effects.
| Experience Level | Dose | Frequency | Cycle Length |
|---|---|---|---|
| Beginner | 0.25 mg | 1x/week | 4 weeks |
| Intermediate | 0.5 mg - 1.0 mg | 1x/week | 4-8 weeks |
| Advanced | 1.7 mg - 2.4 mg | 1x/week | Maintenance |
Reconstitution: Typically comes pre-mixed in pens (e.g., Wegovy, Ozempic) or as a lyophilized powder requiring reconstitution with bacteriostatic water. Injection Site: Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate sites weekly. Missed Dose: If a dose is missed and the next scheduled dose is more than 2 days away, administer the missed dose as soon as possible. If less than 2 days, skip the missed dose and resume the regular schedule.
Community Consensus: community Many users report staying on lower doses (e.g., 0.5 mg or 1.0 mg) if they are still losing weight and experiencing appetite suppression, to minimize side effects.[1]
Nutritional Support & Recommended Supplements.
- Protein: High protein intake (1.5-2.0g/kg body weight) is crucial to preserve lean muscle mass during rapid weight loss.
- Hydration: Increased water intake is necessary to prevent dehydration, especially if experiencing nausea or vomiting.
- Electrolytes: Supplementation may be needed if dietary intake is significantly reduced.
Safety, Interactions & Side Effect Management.
Side Effects:
- Nausea, vomiting, diarrhea, constipation (Very Common, well-established)
- Fatigue, headache (Common, well-established)
- Hypoglycemia (in patients with T2D on other meds) (Common, well-established)
Contraindications (Absolute):
- Personal or family history of medullary thyroid carcinoma (MTC)[7][8]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Contraindications (Relative):
- History of pancreatitis[6]
- Severe gastrointestinal disease
Red Flags:
- Severe, persistent abdominal pain (potential pancreatitis)
- Changes in vision (potential diabetic retinopathy complications)
Pregnancy/Lactation/Fertility:
- Contraindicated during pregnancy. Discontinue at least 2 months before a planned pregnancy.
Common Stacks & Combinations.
Semaglutide is often used as a standalone therapy due to its potency.
| Stack | Rationale | Severity |
|---|---|---|
| Semaglutide + BPC-157 | BPC-157 may help mitigate gastrointestinal side effects. | Low |
| Semaglutide + AOD-9604 | Synergistic fat loss. | Low |
Anti-Pattern Stacks:
| Stack | Rationale | Severity |
|---|---|---|
| Semaglutide + Other GLP-1 RAs | Increased risk of severe hypoglycemia and GI distress. | High |
Body Composition & Training Guide.
Semaglutide leads to significant reductions in both fat mass and lean mass. Resistance training is essential to mitigate muscle loss.
| Phase | Expected Trajectory |
|---|---|
| Weeks 1-4 | Initial weight loss, primarily water and some fat. |
| Weeks 5-12 | Accelerated fat loss as dose increases. |
| Months 3-6 | Sustained weight loss, potential plateau requiring dose adjustment or diet modification. |
Contexts:
- Hypertrophy: Difficult due to caloric deficit. Focus on muscle maintenance.
- Fat Loss: Highly effective.
Storage, Handling & Accessibility.
- Storage (Unreconstituted/Unopened): Refrigerate at 2°C to 8°C (36°F to 46°F).
- Storage (Reconstituted/Opened): Can be kept at room temperature (up to 30°C/86°F) or refrigerated for up to 56 days.
- Accessibility: Available by prescription (Wegovy, Ozempic) or through compounding pharmacies.
Bloodwork Monitoring Guide.
Baseline Panel:
- Comprehensive Metabolic Panel (CMP)
- Lipid Panel
- HbA1c
- Thyroid Stimulating Hormone (TSH)
Mid-Cycle (3-6 months):
- Re-evaluate HbA1c and Lipid Panel.
- Monitor renal function (BUN/Creatinine) if experiencing severe GI symptoms.
Doctor Handoff Note: "Patient is initiating semaglutide therapy for weight management. Please monitor for signs of pancreatitis, gallbladder disease, and changes in renal function, especially if severe GI adverse events occur."
Comparison to Similar Compounds.
| Compound | Primary Mechanism | Key Difference | When to Pick |
|---|---|---|---|
| Semaglutide | GLP-1 RA | Highly potent, once-weekly dosing. | Standard choice for significant weight loss. |
| Tirzepatide | Dual GIP/GLP-1 RA | Greater weight loss efficacy in trials. | When semaglutide is ineffective or greater weight loss is desired. |
| Liraglutide | GLP-1 RA | Daily dosing (Saxenda). | If once-weekly dosing is not tolerated. |
Deep Dive (For Advanced Researchers).
Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. It has a prolonged half-life of approximately 1 week, achieved through structural modifications including the addition of a fatty acid diacid chain, which promotes binding to albumin and delays renal clearance.
Mechanism of Action: It binds to and activates the GLP-1 receptor, leading to increased cAMP levels, which stimulates glucose-dependent insulin release and inhibits glucagon secretion. It also acts centrally to reduce appetite. well-established[2]
Clinical Trials:
| Trial | Year | Focus | Key Finding |
|---|---|---|---|
| Wilding et al. (STEP 1 [1]) | 2021 | Weight loss in obesity | 14.9% mean weight loss at 68 weeks.[3] |
| Rubino et al. (STEP 4 [4]) | 2021 | Sustained weight loss | Continued weight loss with ongoing treatment vs. regain with placebo.[4] |
| Lincoff et al. (SELECT) | 2023 | Cardiovascular outcomes | 20% reduction in major adverse cardiovascular events.[5] |
Active Metabolites: Semaglutide is degraded by proteolytic cleavage and beta-oxidation of the fatty acid side chain.
Open Questions: Long-term effects on muscle mass quality and the durability of weight loss post-discontinuation.
Frequently Asked Questions (FAQ).
- How fast will I lose weight? Weight loss varies, but clinical trials show significant results within the first few months.
- Do I have to stay on it forever? Weight regain is common after discontinuation, suggesting it may be a chronic treatment for many.
- What are the most common side effects? Nausea, diarrhea, and vomiting, especially during dose escalation.
- Can I drink alcohol? Alcohol can exacerbate GI side effects and increase the risk of hypoglycemia.
- How do I manage nausea? Eat smaller meals, avoid high-fat foods, and stay hydrated.
- Is it safe for long-term use? Current data supports long-term safety, but ongoing monitoring is recommended.[6]
- Does it cause muscle loss? Weight loss includes both fat and lean mass; resistance training and adequate protein are essential.
International Regulatory Status.
| Agency | Status | Notes |
|---|---|---|
| US FDA | Approved | As Wegovy (weight loss)[7] and Ozempic (T2D)[8]. |
| UK MHRA | Approved | Available for weight management and T2D. |
| EU EMA | Approved | Available for weight management and T2D. |
| Health Canada | Approved | Available for weight management and T2D. |
| Australia TGA | Approved | Available for weight management and T2D. |
| WADA | Not Prohibited | Not on the prohibited list. |
Decision Tree.
[Goal: Weight Loss?]
|--(No)--> STOP. Semaglutide is primarily for weight loss and glycemic control.
|--(Yes)--> [History of Medullary Thyroid Carcinoma or MEN 2?]
|--(Yes)--> STOP. Absolute contraindication.
|--(No)--> [Willing to commit to long-term lifestyle changes?]
|--(No)--> Reconsider. Weight regain is likely upon discontinuation.
|--(Yes)--> Semaglutide is a strong candidate. Start at 0.25 mg/week.What we cited.
- Reddit r/Semaglutide. "dosing protocol". Accessed May 2026. https://www.reddit.com/r/Semaglutide/search/?q=dosing+protocol&sort=top&t=all
- Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. Pharm Res. 2022;39(6):1233-1248. doi:10.1007/s11095-022-03302-1
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(15):1414-1425. doi:10.1001/jama.2021.3224
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
- Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:645563. doi:10.3389/fendo.2021.645563
- FDA Label. WEGOVY (semaglutide) injection, for subcutaneous use.
- FDA Label. OZEMPIC (semaglutide) injection, for subcutaneous use.